Y-27632

Y-27632

SCHEMBL190356

CC(N)C1CCC(C(=O)Nc2ccncc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 8/20 1.00
ROCK1 Q13464 8/20 1.00
PKN2 Q16513 4/20 1.00
RPS6KA5 O75582 3/20 1.00
LRRK2 Q5S007 3/20 1.00
TP53 P04637 2/20 1.00
CYP3A4 P08684 2/20 1.00
PRKD3 O94806 2/20 1.00
CDK1 P06493 2/20 1.00
CDK2 P24941 2/20 1.00
LTK P29376 2/20 1.00
CDK8 P49336 2/20 1.00
PRKX P51817 2/20 1.00
PRKCQ Q04759 2/20 1.00
PRKCD Q05655 2/20 1.00
STK3 Q13188 2/20 1.00
CDC42BPA Q5VT25 2/20 1.00
BRSK1 Q8TDC3 2/20 1.00
CLK4 Q9HAZ1 2/20 1.00
TSHR P16473 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Y-27632 SCHEMBL28416532 1.00 ROCK2 (1.00) ROCK2ROCK1PKN2RPS6KA5LRRK2
Y-27632 SCHEMBL598993 1.00 ROCK2 (1.00) ROCK2ROCK1PKN2RPS6KA5LRRK2
Y-27632 SCHEMBL1980406 1.00 ROCK2 (1.00) ROCK2ROCK1PKN2RPS6KA5LRRK2
Y-27632 SCHEMBL20333114 1.00 ROCK2 (1.00) ROCK2ROCK1PKN2RPS6KA5LRRK2
Y-27632 SCHEMBL18935698 1.00 ROCK2 (1.00) ROCK2ROCK1PKN2RPS6KA5LRRK2
Y-27632 SCHEMBL342816 1.00 ROCK2 (1.00) ROCK2ROCK1PKN2RPS6KA5LRRK2
Y-27632 SCHEMBL30286315 1.00 ROCK2 (1.00) ROCK2ROCK1PKN2RPS6KA5LRRK2
Y-27632 SCHEMBL2796890 0.99 ROCK2 (0.97) ROCK2ROCK1PKN2RPS6KA5LRRK2
Y-27632 SCHEMBL1554110 0.99 ROCK2 (1.00) ROCK2ROCK1PKN2RPS6KA5LRRK2
Y-27632 SCHEMBL2834049 0.99 ROCK2 (1.00) ROCK2ROCK1PKN2RPS6KA5LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 750 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049275-A1 INDUCED STEM CELLS UNIV MONASH (AU) 2026-02-19 US claimed
US-12371664-B2 Medium for direct differentiation of pluripotent stem cell-derived mesenchymal stem cell, method for preparing mesenchymal stem cell by using same, and mesenchymal stem cell prepared thereby CHA BIOTECH CO., LTD. (KR) 2025-07-29 US claimed
US-20250017977-A1 HEPATOCYTES AND HEPATIC NON-PARENCHYMAL CELLS, AND METHODS FOR PREPARATION THEREOF THE UNIVERSITY OF TOKYO (JP) 2025-01-16 US claimed
US-20240245668-A1 AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG SANTEN PHARMACEUTICAL CO., LTD. (JP) 2024-07-25 US claimed
EP-3334820-B1 INDUCED EXTENDED PLURIPOTENT STEM CELLS, METHODS OF MAKING AND USING BEIHAO STEM CELL AND REGENERATIVE MEDICINE RES INSTITUTE CO LTD (CN) 2024-05-15 EP claimed
WO-2024079755-A1 A SCALABLE METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIUM (RPE) CELLS EYESTEM RESEARCH PRIVATE LIMITED (IN) 2024-04-18 WO claimed
EP-3372673-B1 METHOD FOR PRODUCING CEREBELLAR PROGENITOR TISSUE RIKEN (JP) 2023-12-13 EP claimed
US-11839618-B2 Agent for promoting corneal endothelial cell adhesion SENJU PHARMACEUTICAL CO., LTD. (JP) 2023-12-12 US claimed
EP-4251739-A1 INDUCED STEM CELLS Monash University (AU) 2023-10-04 EP claimed
CN-116761882-A Inducible stem cells 莫纳什大学 2023-09-15 CN claimed
US-6649625-B2 Agent for prophylaxis and treatment of glaucoma SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-11-18 US claimed
US-20030165576-A1 Antitumor effect potentiators MITSUBISHI PHARMA CORPORATION (JP) 2003-09-04 US claimed
US-20030125351-A1 Agent for prophylaxis and treatment of glaucoma AZUMA MITSUYOSHI (JP) 2003-07-03 US claimed
US-20030096843-A1 Preventives/remedies for kidney diseases MITSUBISHI PHARMA CORPORATION (JP) 2003-05-22 US claimed
EP-1295607-A1 ANTITUMOR EFFECT POTENTIATORS Mitsubishi Pharma Corporation (JP) 2003-03-26 EP claimed
EP-1177796-A1 PREVENTIVES/REMEDIES FOR LIVER DISEASES Mitsubishi Pharma Corporation (JP) 2002-02-06 EP claimed
EP-1174150-A1 PREVENTIVES/REMEDIES FOR ANGIOSTENOSIS Mitsubishi Pharma Corporation (JP) 2002-01-23 EP claimed
EP-1163910-A1 PREVENTIVES/REMEDIES FOR INTERSTITIAL PNEUMONIA AND PULMONARY FIBROSIS Welfide Corporation (JP) 2001-12-19 EP claimed
EP-1034793-A1 PREVENTIVES/REMEDIES FOR GLAUCOMA Senju Pharmaceutical Co., Ltd. (JP) 2000-09-13 EP claimed
EP-0370498-A2 Trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane compounds and pharmaceutical use thereof YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1990-05-30 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096843-A1 Preventives/remedies for kidney diseases RHOA, ROCK1, MMP1 ROCK2 6/4885ROCK1 2/4885PKN2 808/4885
US-20030125351-A1 Agent for prophylaxis and treatment of glaucoma ROCK1, PDE3A, RHOA ROCK2 10/4885ROCK1 1/4885PKN2 1820/4885
US-20240245668-A1 AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG PTGIS, PTGIR, PTGS1 ROCK2 539/4885ROCK1 725/4885PKN2 2185/4885
US-20030165576-A1 Antitumor effect potentiators RHOT2, ROCK2, CIT ROCK2 2/4885ROCK1 5/4885PKN2 388/4885
US-20260049275-A1 INDUCED STEM CELLS SALL4, SOX18, LEF1 ROCK2 991/4885ROCK1 345/4885PKN2 2355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.